Well, two new studies have been published in the New England Journal of Medicine and were presented at the American Society of Clinical Oncology 2010 Annual Meeting.
Here's the story from Medscape:
http://www.medscape.com/viewarticle/723159?sssdmh=dm1.621178&src=nldne&uac=122954PX
These studies should lead to some vigorous debate in the clinical oncologists' community about how to treat CML (chronic myelogenous leukemia).
Gleevec (imatinib) remains a first-of-its-kind medicine. These new successors work on the same principle as imatinib. However, they seem to extend these principles and therefore are more effective.
It remains to be seen if the regulatory bodies will recommend these new kids on the block as first-line therapy for CML. Although, dasatinib and nilotinib have been around now for a few years.
Here's the story from Medscape:
http://www.medscape.com/viewarticle/723159?sssdmh=dm1.621178&src=nldne&uac=122954PX
These studies should lead to some vigorous debate in the clinical oncologists' community about how to treat CML (chronic myelogenous leukemia).
Gleevec (imatinib) remains a first-of-its-kind medicine. These new successors work on the same principle as imatinib. However, they seem to extend these principles and therefore are more effective.
It remains to be seen if the regulatory bodies will recommend these new kids on the block as first-line therapy for CML. Although, dasatinib and nilotinib have been around now for a few years.
Comments
Post a Comment
Feel free to weigh in with your thoughts ...